Cabozantinib

CHICAGO — The addition of CBM588 to immune checkpoint inhibitor-based therapy significantly increased PFS and response rates with no impact on stool microbiome diversity among a small cohort of patients with metastatic renal cell carcinoma.

CHICAGO — The addition of atezolizumab to cabozantinib failed to improve clinical outcomes for patients with metastatic renal cell carcinoma who experienced progression on or after immune checkpoint inhibitor therapy, study results showed.

The combination of belzutifan and cabozantinib showed promising antitumor activity among patients with previously treated metastatic clear cell renal cell carcinoma, according to data published in The Lancet Oncology.

SAN FRANCISCO — Healio spoke with Moshe Ornstein, MD, about the COSMIC-313 trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, highlights findings from the follow-up data of the CheckMate 9ER trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, discusses interim results from the CaboPoint study presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, highlights a biomarker analysis of CheckMate 9ER he presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Healio spoke with Toni K. Choueiri, MD, about follow-up data from the CheckMate 9ER presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, who was the senior author, discusses an analysis of COSMIC-313 presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Nivolumab plus cabozantinib extended OS and PFS compared with sunitinib as first-line treatment for patients with advanced renal cell carcinoma, according to updated results of the randomized phase 3 CheckMate 9ER trial.